Skip to main
  1. Stocks
  2. Celcuity
  3. Forecast
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is well positioned fundamentally because Revtorpyk/gedatolisib has already validated its mechanism in Phase III, with approval in July 2026 for 2L+ HR+/HER2- disease and strong data in both PIK3CA-wildtype and mutant populations supporting a broad, mutation-agnostic label expansion. The commercial case is reinforced by an estimated ~60% of the 2L population being PIK3CA-wildtype at launch, survey-based expectations for ~39% peak penetration, and management’s ability to support adoption through completed payer engagement, distribution, and a 120-day payment window. Beyond the breast-cancer base, the ongoing VIKTORIA-2 and mCRPC programs provide additional upside, while the company’s path to roughly $2.4B peak sales across WT and mutant disease underpins a positive outlook.

Bears say

Celcuity is a clinical-stage biotech with no approved revenue base, so its valuation depends heavily on gedatolisib executing across late-stage trials and a launch that still faces reimbursement, manufacturing, and formulary friction. The bear case centers on adoption barriers rather than biology alone: weekly IV dosing, stomatitis, and buy-and-bill delays could slow uptake, while community oncologists may favor convenient oral competitors even at modest efficacy tradeoffs. Fundamentally, the company also faces a high clinical bar in HR+/HER2- breast cancer, where existing CDK4/6 inhibitor plus aromatase inhibitor regimens have shown median PFS of 25-28 months and multiple Phase 3 efforts have failed to improve on standard of care.

Celcuity (CELC) has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Celcuity (CELC) Analyst Forecast & Price Prediction

Get the latest Celcuity (CELC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Celcuity (CELC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 12 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Nov 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Celcuity (CELC) Analyst Forecast & Price Prediction

Get the latest Celcuity (CELC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Celcuity (CELC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CELC stock data and trends